AtriCure, Inc. $ATRC Stock Holdings Lifted by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in AtriCure, Inc. (NASDAQ:ATRC) by 1.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 755,537 shares of the medical device company’s stock after buying an additional 7,731 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 1.52% of AtriCure worth $24,759,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the stock. Teacher Retirement System of Texas grew its holdings in shares of AtriCure by 5.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock worth $246,000 after acquiring an additional 385 shares during the last quarter. US Bancorp DE boosted its position in shares of AtriCure by 98.1% in the 1st quarter. US Bancorp DE now owns 1,593 shares of the medical device company’s stock valued at $51,000 after purchasing an additional 789 shares during the period. First Horizon Advisors Inc. lifted its stake in AtriCure by 135.3% during the first quarter. First Horizon Advisors Inc. now owns 1,447 shares of the medical device company’s stock valued at $47,000 after buying an additional 832 shares in the last quarter. AQR Capital Management LLC lifted its stake in AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after buying an additional 837 shares in the last quarter. Finally, CWM LLC lifted its stake in AtriCure by 46.2% during the first quarter. CWM LLC now owns 2,818 shares of the medical device company’s stock valued at $91,000 after buying an additional 891 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ATRC. Canaccord Genuity Group boosted their price target on shares of AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Needham & Company LLC lifted their price objective on shares of AtriCure from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. BTIG Research set a $54.00 target price on AtriCure in a research report on Wednesday, July 30th. Finally, Wall Street Zen raised AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and a consensus target price of $52.22.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $32.75 on Wednesday. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -53.69 and a beta of 1.59. AtriCure, Inc. has a 1 year low of $28.29 and a 1 year high of $43.11. The company has a current ratio of 3.94, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16. The business has a fifty day simple moving average of $35.85 and a 200 day simple moving average of $33.99.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.10. AtriCure had a negative return on equity of 2.56% and a negative net margin of 5.55%.The firm had revenue of $134.27 million during the quarter, compared to analysts’ expectations of $131.25 million. During the same quarter last year, the firm earned ($0.17) earnings per share. The business’s revenue for the quarter was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. As a group, sell-side analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Activity at AtriCure

In other AtriCure news, Director Sven Wehrwein sold 5,000 shares of AtriCure stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $37.00, for a total value of $185,000.00. Following the completion of the sale, the director directly owned 34,374 shares in the company, valued at $1,271,838. The trade was a 12.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Justin J. Noznesky sold 3,000 shares of AtriCure stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $36.30, for a total transaction of $108,900.00. Following the completion of the sale, the insider owned 83,964 shares of the company’s stock, valued at $3,047,893.20. This trade represents a 3.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 13,000 shares of company stock valued at $473,900. 3.50% of the stock is currently owned by company insiders.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.